For research use only. Not for therapeutic Use.
Cedirogant (ABBV-157) is an orally active RORγt inverse agonist. Cedirogant can be used for psoriasis research[1][2].
The transcription factor retinoic acid-related orphan receptor gamma t (RORγt) has been identified as the master regulator of TH17 cell differentiation and IL-17/22 production and is therefore an attractive target for the treatment of inflammatory diseases. Cedirogant (ABBV-157) has the potential for chronic plaque psoriasis research[1].
| Catalog Number | I024304 |
| CAS Number | 2055496-11-0 |
| Synonyms | 2-[1-[2,4-dichloro-3-[[7-chloro-5-(trifluoromethyl)indol-1-yl]methyl]benzoyl]piperidin-4-yl]acetic acid |
| Molecular Formula | C24H20Cl3F3N2O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C24H20Cl3F3N2O3/c25-18-2-1-16(23(35)31-6-3-13(4-7-31)9-20(33)34)21(27)17(18)12-32-8-5-14-10-15(24(28,29)30)11-19(26)22(14)32/h1-2,5,8,10-11,13H,3-4,6-7,9,12H2,(H,33,34) |
| InChIKey | MNEOHCYSHVKLIC-UHFFFAOYSA-N |
| SMILES | C1CN(CCC1CC(=O)O)C(=O)C2=C(C(=C(C=C2)Cl)CN3C=CC4=CC(=CC(=C43)Cl)C(F)(F)F)Cl |
| Reference | [1]. Elena Campione, et al. Experimental Pharmacological Management of Psoriasis. J Exp Pharmacol. 2021 Jul 26;13:725-737. [2]. Christian Gege. Retinoic acid-related orphan receptor gamma t (RORγt) inverse agonists/antagonists for the treatment of inflammatory diseases – where are we presently? Expert Opin Drug Discov. 2021 Jul 7;1-19. |
